Telaprevir (BioDeep_00000615049)
代谢物信息卡片
(3S)-3-{[(1S,3aR,6aS)-2-[(2S)-2-[(2S)-2-cyclohexyl-2-(pyrazin-2-ylformamido)acetamido]-3,3-dimethylbutanoyl]-octahydrocyclopenta[c]pyrrol-1-yl]formamido}-N-cyclopropyl-2-oxohexanamide
化学式: C36H53N7O6 (679.4057118000001)
中文名称: 特拉匹韦
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCCC(C(=O)C(=O)NC1CC1)NC(=O)C2C3CCCC3CN2C(=O)C(C(C)(C)C)NC(=O)C(C4CCCCC4)NC(=O)C5=NC=CN=C5
InChI: InChI=1S/C36H53N7O6/c1-5-10-25(29(44)34(48)39-23-15-16-23)40-33(47)28-24-14-9-13-22(24)20-43(28)35(49)30(36(2,3)4)42-32(46)27(21-11-7-6-8-12-21)41-31(45)26-19-37-17-18-38-26/h17-19,21-25,27-28,30H,5-16,20H2,1-4H3,(H,39,48)(H,40,47)(H,41,45)(H,42,46)/t22-,24-,25-,27-,28-,30+/m0/s1
描述信息
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AP - Antivirals for treatment of hcv infections
C254 - Anti-Infective Agent > C281 - Antiviral Agent
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
同义名列表
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:68595
- KEGGdrug: D09012
- PubChem: 3010818
- Metlin: METLIN85554
- DrugBank: DB05521
- ChEMBL: CHEMBL231813
- CAS: 402957-28-2
- CAS: 569364-34-7
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Emily G Hicks, Sylvie E Kandel, Jed N Lampe. Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (Mpro) inhibitors.
Bioorganic & medicinal chemistry letters.
2022 06; 66(?):128732. doi:
10.1016/j.bmcl.2022.128732. [PMID: 35427739] - Adita Ayu Permanasari, Chie Aoki-Utsubo, Tutik Sri Wahyuni, Lidya Tumewu, Myrna Adianti, Aty Widyawaruyanti, Hak Hotta, Achmad Fuad Hafid. An in vitro study of an Artocarpus heterophyllus substance as a hepatitis C antiviral and its combination with current anti-HCV drugs.
BMC complementary medicine and therapies.
2021 Oct; 21(1):260. doi:
10.1186/s12906-021-03408-w. [PMID: 34641875] - Xavier Woot de Trixhe, Wojciech Krzyzanski, An Vermeulen, Juan José Perez-Ruixo. Multiscale model of hepatitis C virus dynamics in plasma and liver following combination therapy.
CPT: pharmacometrics & systems pharmacology.
2021 08; 10(8):826-838. doi:
10.1002/psp4.12604. [PMID: 34296543] - Aditya K Padhi, Timir Tripathi. Targeted design of drug binding sites in the main protease of SARS-CoV-2 reveals potential signatures of adaptation.
Biochemical and biophysical research communications.
2021 05; 555(?):147-153. doi:
10.1016/j.bbrc.2021.03.118. [PMID: 33813274] - Daniel W Kneller, Gwyndalyn Phillips, Kevin L Weiss, Qiu Zhang, Leighton Coates, Andrey Kovalevsky. Direct Observation of Protonation State Modulation in SARS-CoV-2 Main Protease upon Inhibitor Binding with Neutron Crystallography.
Journal of medicinal chemistry.
2021 04; 64(8):4991-5000. doi:
10.1021/acs.jmedchem.1c00058. [PMID: 33755450] - Jingxin Qiao, Yue-Shan Li, Rui Zeng, Feng-Liang Liu, Rong-Hua Luo, Chong Huang, Yi-Fei Wang, Jie Zhang, Baoxue Quan, Chenjian Shen, Xin Mao, Xinlei Liu, Weining Sun, Wei Yang, Xincheng Ni, Kai Wang, Ling Xu, Zi-Lei Duan, Qing-Cui Zou, Hai-Lin Zhang, Wang Qu, Yang-Hao-Peng Long, Ming-Hua Li, Rui-Cheng Yang, Xiaolong Liu, Jing You, Yangli Zhou, Rui Yao, Wen-Pei Li, Jing-Ming Liu, Pei Chen, Yang Liu, Gui-Feng Lin, Xin Yang, Jun Zou, Linli Li, Yiguo Hu, Guang-Wen Lu, Wei-Min Li, Yu-Quan Wei, Yong-Tang Zheng, Jian Lei, Shengyong Yang. SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model.
Science (New York, N.Y.).
2021 03; 371(6536):1374-1378. doi:
10.1126/science.abf1611. [PMID: 33602867] - Raj Kumar, Vikas Kumar, Keun Woo Lee. A computational drug repurposing approach in identifying the cephalosporin antibiotic and anti-hepatitis C drug derivatives for COVID-19 treatment.
Computers in biology and medicine.
2021 03; 130(?):104186. doi:
10.1016/j.compbiomed.2020.104186. [PMID: 33360831] - Nikhil Pathak, Yun-Ti Chen, Yen-Chao Hsu, Nung-Yu Hsu, Chih-Jung Kuo, Hui Ping Tsai, Jaw-Jou Kang, Chih-Heng Huang, Sui-Yuan Chang, Yu-Hsiu Chang, Po-Huang Liang, Jinn-Moon Yang. Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing.
ACS nano.
2021 01; 15(1):857-872. doi:
10.1021/acsnano.0c07383. [PMID: 33373194] - Stefania Bartoloni, Stefano Leone, Filippo Acconcia. Unexpected Impact of a Hepatitis C Virus Inhibitor on 17β-Estradiol Signaling in Breast Cancer.
International journal of molecular sciences.
2020 May; 21(10):. doi:
10.3390/ijms21103418. [PMID: 32408555] - Tutik Sri Wahyuni, Humairoh Mahfud, Adita Ayu Permatasari, Aty Widyawaruyanti, Achmad Fuad. Synergistic anti-hepatitis C virus activity of Ruta angustifolia extract with NS3 protein inhibitor.
Journal of basic and clinical physiology and pharmacology.
2019 Dec; 30(6):. doi:
10.1515/jbcpp-2019-0348. [PMID: 31837259] - Hiroyuki Murata, Soichiro Ito, Hiroyuki Kusuhara, Yukihiro Nomura, Toshio Taniguchi. Proposal of a Parameter for OATP1B1 Inhibition Screening at the Early Drug Discovery Stage.
Journal of pharmaceutical sciences.
2019 12; 108(12):3898-3902. doi:
10.1016/j.xphs.2019.08.012. [PMID: 31446145] - Midori Kjellin, Terése Wesslén, Erik Löfblad, Johan Lennerstrand, Anders Lannergård. The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort.
Upsala journal of medical sciences.
2018 Mar; 123(1):50-56. doi:
10.1080/03009734.2018.1441928. [PMID: 29536805] - Georgia Skardasi, Annie Y Chen, Tomasz I Michalak. Authentic Patient-Derived Hepatitis C Virus Infects and Productively Replicates in Primary CD4+ and CD8+ T Lymphocytes In Vitro.
Journal of virology.
2018 02; 92(3):. doi:
10.1128/jvi.01790-17. [PMID: 29167333] - Yewon Choi, Seonghae Yoon, Kyoko Matsumoto, Yoshiyasu Ohta, SeungHwan Lee, Kyung-Sang Yu, In-Jin Jang. Pharmacokinetic characteristics of telaprevir in healthy Korean male subjects and comparisons with Japanese.
Drug design, development and therapy.
2018; 12(?):1045-1051. doi:
10.2147/dddt.s148117. [PMID: 29750017] - R Maan, S H Al Marzooqi, J S Klair, J Karkada, O Cerocchi, M Kowgier, S M Harrell, K D Rhodes, H L A Janssen, J J Feld, A Duarte-Rojo. The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens.
Alimentary pharmacology & therapeutics.
2017 07; 46(1):46-55. doi:
10.1111/apt.14117. [PMID: 28470850] - Lydia Plana, Laura Peño, Juan José Urquijo, Moisés Diago. Difficult management of triple therapy for chronic hepatitis C in a patient on haemodialysis.
Gastroenterologia y hepatologia.
2017 05; 40(5):356-358. doi:
10.1016/j.gastrohep.2016.02.012. [PMID: 27048917] - Satoshi Yamagiwa, Toru Ishikawa, Nobuo Waguri, Soichi Sugitani, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Hirokazu Kawai, Shuji Terai. Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C.
International journal of medical sciences.
2017; 14(5):403-411. doi:
10.7150/ijms.18784. [PMID: 28539815] - Yoko Yamagiwa, Mai Asano, Youhei Kawasaki, Masaaki Korenaga, Kazumoto Murata, Tatsuya Kanto, Masashi Mizokami, Naohiko Masaki. Pretreatment serum levels of interferon-gamma-inducible protein-10 are associated with virologic response to telaprevir-based therapy.
Cytokine.
2016 12; 88(?):29-36. doi:
10.1016/j.cyto.2016.07.004. [PMID: 27541605] - Lotte G van Vlerken, Faydra I Lieveld, Suzanne van Meer, Ger H Koek, Karin M J van Nieuwkerk, Pieter Friederich, Joop E Arends, Peter D Siersema, David M Burger, Karel J van Erpecum. Adherence to ribavirin in chronic hepatitis C patients on antiviral treatment: Results from a randomized controlled trial using real-time medication monitoring.
Clinics and research in hepatology and gastroenterology.
2016 Nov; 40(5):622-630. doi:
10.1016/j.clinre.2015.12.014. [PMID: 26867863] - Xavier Forns, Samuel Didier, David Mutimer, Stefano Fagiuoli, Miquel Navasa, Kosh Agarwal, Marina Berenguer, Massimo Colombo, Kerstin Herzer, Frederik Nevens, Bjorn Daems, Katrien Janssen, Sivi Ouwerkerk-Mahadevan, Holly Kimko, Erkki Lathouwers, James Witek, Rodica Van Solingen-Ristea. Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C.
Annals of hepatology.
2016 Jul; 15(4):512-23. doi:
NULL. [PMID: 27236150] - Xi-Jing Qian, Xiao-Lian Zhang, Ping Zhao, Yong-Sheng Jin, Hai-Sheng Chen, Qing-Qiang Xu, Hao Ren, Shi-Ying Zhu, Hai-Lin Tang, Yong-Zhe Zhu, Zhong-Tian Qi. A Schisandra-Derived Compound Schizandronic Acid Inhibits Entry of Pan-HCV Genotypes into Human Hepatocytes.
Scientific reports.
2016 06; 6(?):27268. doi:
10.1038/srep27268. [PMID: 27252043] - Dadan Ramadhan Apriyanto, Chie Aoki, Sri Hartati, Muhammad Hanafi, Leonardus Broto Sugeng Kardono, Ade Arsianti, Melva Louisa, Tjahjani Mirawati Sudiro, Beti Ernawati Dewi, Pratiwi Sudarmono, Amin Soebandrio, Hak Hotta. Anti-Hepatitis C Virus Activity of a Crude Extract from Longan (Dimocarpus longan Lour.) Leaves.
Japanese journal of infectious diseases.
2016 May; 69(3):213-20. doi:
10.7883/yoken.jjid.2015.107. [PMID: 26255732] - Hiroki Ikeda, Chiaki Okuse, Tsunamasa Watanabe, Nobuyuki Matsumoto, Kotaro Matsunaga, Ryuta Shigefuku, Nobuhiro Hattori, Tetsuya Hiraishi, Yasunobu Fukuda, Yohei Noguchi, Toshiya Ishii, Junko Shima, Kazunari Nakahara, Hiroyuki Yamamoto, Hiroshi Yasuda, Hiroshi Yotsuyanagi, Kazuhiko Koike, Fumio Itoh, Michihiro Suzuki. Can the Abbott RealTime hepatitis C virus assay be used to predict therapeutic outcomes in hepatitis C virus-infected patients undergoing triple therapy?.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.
2016 Mar; 27(2):165-72. doi:
10.5152/tjg.2016.150300. [PMID: 27015621] - Tim Zimmermann, Dietrich Hueppe, Stefan Mauss, Peter Buggisch, Heike Pfeiffer-Vornkahl, Daniel Grimm, Peter R Galle, Ulrich Alshuth. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
Journal of gastrointestinal and liver diseases : JGLD.
2016 Mar; 25(1):15-24. doi:
10.15403/jgld.2014.1121.251.a2a. [PMID: 27014750] - Jun-Jun Cheng, Jian-Rui Li, Meng-Hao Huang, Lin-Lin Ma, Zhou-Yi Wu, Chen-Chen Jiang, Wen-Jing Li, Yu-Huan Li, Yan-Xing Han, Hu Li, Jin-Hua Chen, Yan-Xiang Wang, Dan-Qing Song, Zong-Gen Peng, Jian-Dong Jiang. CD36 is a co-receptor for hepatitis C virus E1 protein attachment.
Scientific reports.
2016 Feb; 6(?):21808. doi:
10.1038/srep21808. [PMID: 26898231] - K Ura, N Furusyo, E Ogawa, T Hayashi, H Mukae, M Shimizu, K Toyoda, M Murata, J Hayashi. Serum WFA(+) -M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C.
Alimentary pharmacology & therapeutics.
2016 Jan; 43(1):114-24. doi:
10.1111/apt.13431. [PMID: 26503582] - Min Yao, Xin Lu, Yingfeng Lei, Jing Yang, Haiwei Zhao, Qinghua Qiao, Peijun Han, Zhikai Xu, Wen Yin. Conditional Inducible Triple-Transgenic Mouse Model for Rapid Real-Time Detection of HCV NS3/4A Protease Activity.
PloS one.
2016; 11(3):e0150894. doi:
10.1371/journal.pone.0150894. [PMID: 26943641] - Tatsuo Kanda, Shingo Nakamoto, Reina Sasaki, Masato Nakamura, Shin Yasui, Yuki Haga, Sadahisa Ogasawara, Akinobu Tawada, Makoto Arai, Shigeru Mikami, Fumio Imazeki, Osamu Yokosuka. Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin.
International journal of medical sciences.
2016; 13(4):310-5. doi:
10.7150/ijms.14953. [PMID: 27076789] - Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Hideyuki Nomura, Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Takeaki Satoh, Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi. Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection.
Journal of gastroenterology and hepatology.
2015 Dec; 30(12):1759-67. doi:
10.1111/jgh.13016. [PMID: 26095167] - S Akhan, M Sayan, E Sargin Altunok, A Aynioglu. A case report: antiviral triple therapy with telaprevir in a haemodialysed HCV patient in Turkey.
Acta clinica Belgica.
2015 Dec; 70(6):440-1. doi:
10.1080/17843286.2015.1107199. [PMID: 26790555] - Michio Imamura, Kazuaki Chayama. [Telaprevir, peginterferon and ribavirin therapy for chronic hepatitis C].
Nihon rinsho. Japanese journal of clinical medicine.
2015 Dec; 73 Suppl 9(?):243-7. doi:
NULL. [PMID: 26845938] - Makoto Nakamuta, Motoyuki Kohjima. [Effects of telaprevir (TVR) on cholesterol metabolism].
Nihon rinsho. Japanese journal of clinical medicine.
2015 Dec; 73 Suppl 9(?):199-203. doi:
". [PMID: 26845930] - Ming-Ming Cao, Yu Zhang, Sheng-Dian Huang, Ying-Tong Di, Zong-Gen Peng, Jian-Dong Jiang, Chun-Mao Yuan, Duo-Zhi Chen, Shun-Lin Li, Hong-Ping He, Xiao-Jiang Hao. Alkaloids with Different Carbon Units from Myrioneuron faberi.
Journal of natural products.
2015 Nov; 78(11):2609-16. doi:
10.1021/acs.jnatprod.5b00543. [PMID: 26551513] - Amedeo De Nicolò, Adnan Mohamed Abdi, Lucio Boglione, Lorena Baiett, Sarah Allegra, Giovanni Di Perri, Antonio D'Avolio. UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells.
Journal of pharmaceutical and biomedical analysis.
2015 Nov; 115(?):443-9. doi:
10.1016/j.jpba.2015.08.004. [PMID: 26291788] - Katsuomi Matsui, Atsuko Kamijo-Ikemori, Takeshi Sugaya, Hiroki Ikeda, Chiaki Okuse, Yugo Shibagaki, Takashi Yasuda, Kenjiro Kimura. Does elevation of serum creatinine in patients with chronic hepatitis C under therapy of telaprevir mean renal impairment?.
Nephrology (Carlton, Vic.).
2015 Nov; 20(11):843-8. doi:
10.1111/nep.12517. [PMID: 25998031] - Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, Noritomo Shimada, Hiroshi Abe, Norio Itokawa, Ai Nakagawa, Tomomi Okubo, Yoshio Aizawa, Katsuhiko Iwakiri. Vitamin D-related gene polymorphisms do not influence the outcome and serum vitamin D level in pegylated interferon/ribavirin therapy combined with protease inhibitor for patients with genotype 1b chronic hepatitis C.
Journal of medical virology.
2015 Nov; 87(11):1904-12. doi:
10.1002/jmv.24244. [PMID: 25964133] - Barbara Bartolini, Marina Selleri, Anna Rosa Garbuglia, Emanuela Giombini, Chiara Taibi, Raffaella Lionetti, Gianpiero D'Offizi, Maria R Capobianchi. HCV NS3 quasispecies in liver and plasma and dynamics of telaprevir-resistant variants in breakthrough patients assessed by UDPS: A case study.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
2015 Nov; 72(?):60-5. doi:
10.1016/j.jcv.2015.07.310. [PMID: 26418073] - Corrien P W G M Verweij-van Wissen, Marga J A de Graaff-Teulen, Clara T M M de Kanter, Rob E Aarnoutse, David M Burger. Determination of the HCV Protease Inhibitor Telaprevir in Plasma and Dried Blood Spot by Liquid Chromatography-Tandem Mass Spectrometry.
Therapeutic drug monitoring.
2015 Oct; 37(5):626-33. doi:
10.1097/ftd.0000000000000189. [PMID: 25627404] - Sivi Ouwerkerk-Mahadevan, Atef Halabi, Blanka Cieslarová, Indra Aerts, James Witek, Rodica Van Solingen-Ristea, Donghan Luo. Pharmacokinetics of bound and unbound telaprevir in cirrhotic patients with moderate and severe hepatic impairment.
Journal of clinical pharmacology.
2015 Oct; 55(10):1147-56. doi:
10.1002/jcph.545. [PMID: 25975934] - Ewa Janczewska, Robert Flisiak, Dorota Zarebska-Michaluk, Dorota Kozielewicz, Hanna Berak, Beata Dobracka, Marta Librant-Suska, Wladyslaw Lojewski, Krzysztof Jurczyk, Joanna Musialik, Barbara Postawa-Klosińska, Jacek Wroblewski, Krystyna Augustyniak, Marek Dudziak, Iwona Olszok, Agata Ruszala, Arkadiusz Pisula, Tadeusz Lapinski, Wieslaw Kryczka, Andrzej Horban, Witold Dobracki. Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study.
Medicine.
2015 Sep; 94(38):e1411. doi:
10.1097/md.0000000000001411. [PMID: 26402801] - Safak Kaya, Selcuk Aksoz, Birol Baysal, Nurettin Ay, Ramazan Danis. Evaluation of telaprevir-containing triple therapy in the treatment of chronic hepatitis C in hemodialysed patients.
Infectious diseases (London, England).
2015 Sep; 47(9):658-61. doi:
10.3109/23744235.2015.1034769. [PMID: 25936530] - Anna Rosa Garbuglia, Raffaella Lionetti, Daniele Lapa, Chiara Taibi, Ubaldo Visco-Comandini, Marzia Montalbano, Gianpiero D'Offizi, Filippo Castiglione, Maria Rosaria Capobianchi, Paola Paci. The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
2015 Aug; 69(?):68-73. doi:
10.1016/j.jcv.2015.06.002. [PMID: 26209382] - J E Arends, J T M van der Meer, D Posthouwer, W Kortmann, K Brinkman, S van Assen, C Smit, M van der Valk, M van der Ende, J Schinkel, P Reiss, C Richter, A I M Hoepelman. Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients.
The Netherlands journal of medicine.
2015 Aug; 73(7):324-30. doi:
NULL. [PMID: 26314715] - Philippe Sultanik, Vincent Mallet, Sylvie Lagaye, Armanda Casrouge, Céline Dorival, Yoann Barthe, Hélène Fontaine, Christophe Hézode, Estelle Mottez, Jean-Pierre Bronowicki, Fabrice Carrat, Ioannis Theodorou, Laurent Abel, Etienne Gayat, Arnaud Fontanet, Stanislas Pol, Matthew L Albert. Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.
Liver international : official journal of the International Association for the Study of the Liver.
2015 Jul; 35(7):1833-44. doi:
10.1111/liv.12759. [PMID: 25556540] - Sonya A MacParland, Annie Y Chen, Christopher P Corkum, Tram N Q Pham, Tomasz I Michalak. Patient-derived hepatitis C virus inhibits CD4⁺ but not CD8⁺ T lymphocyte proliferation in primary T cells.
Virology journal.
2015 Jun; 12(?):93. doi:
10.1186/s12985-015-0322-4. [PMID: 26084511] - Eva Van den Eynde, Jordi Curto, Elena Ferrer, Arkaitz Imaz, Maria Saumoy, Silvana Di Yacovo, Antonia Vila, Daniel Podzamczer. Telaprevir decreases estimated glomerular filtration rate in HIV-hepatitis C virus coinfected patients.
AIDS (London, England).
2015 May; 29(8):977-9. doi:
10.1097/qad.0000000000000643. [PMID: 25784438] - Laura Milazzo, Dario Cattaneo, Elisa Calvi, Cristina Gervasoni, Cristina Mazzali, Paola Ronzi, Anna Maria Peri, Anna Lisa Ridolfo, Antonio D'Avolio, Spinello Antinori. Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders.
International journal of antimicrobial agents.
2015 May; 45(5):545-9. doi:
10.1016/j.ijantimicag.2014.12.035. [PMID: 25769784] - Sandra Bodeau, Eric Nguyen-Khac, Caroline Solas, Youssef Bennis, Dominique Capron, Gilles Duverlie, Etienne Brochot. Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations.
Journal of clinical pharmacology.
2015 May; 55(5):517-24. doi:
10.1002/jcph.454. [PMID: 25535910] - Koji Takayama, Norihiro Furusyo, Eiichi Ogawa, Hiroaki Ikezaki, Motohiro Shimizu, Masayuki Murata, Jun Hayashi. Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients.
World journal of gastroenterology.
2015 Apr; 21(15):4696-706. doi:
10.3748/wjg.v21.i15.4696. [PMID: 25914481] - Liviawati S Wu, Joseph E Rower, James R Burton, Peter L Anderson, Kyle P Hammond, Fafa Baouchi-Mokrane, Gregory T Everson, Thomas J Urban, David Z D'Argenio, Jennifer J Kiser. Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection.
Antimicrobial agents and chemotherapy.
2015 Apr; 59(4):2179-88. doi:
10.1128/aac.04618-14. [PMID: 25645847] - Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Ryoko Yamada, Naoki Harada, Naoki Morishita, Akira Yamada, Masahide Oshita, Akira Kaneko, Kunio Suzuki, Yoshiaki Inui, Shinji Tamura, Harumasa Yoshihara, Yasuharu Imai, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Akinori Kasahara, Norio Hayashi, Tetsuo Takehara. The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.
Journal of gastroenterology.
2015 Mar; 50(3):313-22. doi:
10.1007/s00535-014-0965-8. [PMID: 24806033] - Jessica Cusato, Sarah Allegra, Amedeo De Nicolò, Lucio Boglione, Giovanna Fatiguso, Giuseppe Cariti, Alessia Ciancio, Antonina Smedile, Silvia Strona, Giulia Troshina, Mario Rizzetto, Giovanni Di Perri, Antonio D'Avolio. ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2015 Feb; 69(?):63-9. doi:
10.1016/j.biopha.2014.11.007. [PMID: 25661339] - Sayeh Ezzikouri, Tomohiro Nishimura, Michinori Kohara, Soumaya Benjelloun, Yoichiro Kino, Kazuaki Inoue, Akira Matsumori, Kyoko Tsukiyama-Kohara. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
Antiviral research.
2015 Jan; 113(?):93-102. doi:
10.1016/j.antiviral.2014.10.017. [PMID: 25446333] - Jessica Cusato, Sarah Allegra, Amedeo De Nicolò, Lucio Boglione, Giovanna Fatiguso, Adnan Mohamed Abdi, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio. Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir.
Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
2015; 18(2):171-6. doi:
10.18433/j3dk6t. [PMID: 26158282] - Annie Y Chen, Matthew Hoare, Arun N Shankar, Michael Allison, Graeme J M Alexander, Tomasz I Michalak. Persistence of Hepatitis C Virus Traces after Spontaneous Resolution of Hepatitis C.
PloS one.
2015; 10(10):e0140312. doi:
10.1371/journal.pone.0140312. [PMID: 26473969] - Harald Farnik, Tim Zimmermann, Eva Herrmann, Wolf O Bechstein, Bernd Kronenberger, Peter R Galle, Sandra Labocha, Nerea Ferreiros, Gerd Geisslinger, Stefan Zeuzem, Christoph Sarrazin, Martin W Welker. Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation.
Liver international : official journal of the International Association for the Study of the Liver.
2015 Jan; 35(1):176-83. doi:
10.1111/liv.12532. [PMID: 24649882] - Alicia Gutierrez-Valencia, Rosa Ruiz-Valderas, Omar J Ben-Marzouk-Hidalgo, Almudena Torres-Cornejo, Nuria Espinosa, Juan R Castillo-Ferrando, Pompeyo Viciana, Luis F Lopez-Cortes. Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy.
Antimicrobial agents and chemotherapy.
2015; 59(6):3257-62. doi:
10.1128/aac.04795-14. [PMID: 25801562] - Karin Neukam, Daniela Munteanu, Sebastian Haubitz, José A Mira, Patrick Ingiliz, Antonio Rivero-Juárez, Thomas Lutz, Ignacio de los Santos-Gil, Stefan Scholten, Manuel Márquez, Andri Rauch, Jürgen K Rockstroh, Juan A Pineda. Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection.
Antiviral therapy.
2015; 20(4):407-13. doi:
10.3851/imp2921. [PMID: 25470790] - K Rajender Reddy, Stefan Zeuzem, Fabien Zoulim, Ola Weiland, Andrzej Horban, Carol Stanciu, Federico Guillermo Villamil, Pietro Andreone, Jacob George, Elisabeth Dammers, Min Fu, Darryl Kurland, Oliver Lenz, Sivi Ouwerkerk-Mahadevan, Thierry Verbinnen, Jane Scott, Wolfgang Jessner. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
The Lancet. Infectious diseases.
2015 Jan; 15(1):27-35. doi:
10.1016/s1473-3099(14)71002-3. [PMID: 25482330] - Meghan E Sise, Elke S Backman, Julia B Wenger, Brian R Wood, Paul E Sax, Raymond T Chung, Ravi Thadhani, Arthur Y Kim. Short and long-term effects of telaprevir on kidney function in patients with hepatitis C virus infection: a retrospective cohort study.
PloS one.
2015; 10(4):e0124139. doi:
10.1371/journal.pone.0124139. [PMID: 25923243] - Akira Kawano, Eiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, Eiji Kajiwara, Kazufumi Dohmen, Hideyuki Nomura, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Yuichi Tanabe, Shinji Shimoda, Kazuhiro Kotoh, Jun Hayashi. Bacterial infection as an adverse effect of telaprevir-based triple therapy for chronic hepatitis C infection.
Internal medicine (Tokyo, Japan).
2015; 54(6):567-72. doi:
10.2169/internalmedicine.54.3457. [PMID: 25790806] - Kayo Sugimoto, Soo Ryang Kim, Soo Ki Kim, Susumu Imoto, Madoka Tohyama, Ke Ih Kim, Aya Ohtani, Takashi Hatae, Yoshihiko Yano, Masatoshi Kudo, Yoshitake Hayashi. Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
Oncology.
2015; 89 Suppl 2(?):42-6. doi:
10.1159/000440630. [PMID: 26584035] - Daisuke Morihara, Hiroshi Watanabe, Kazuhide Takata, Hideyuki Iwashita, Naoaki Tsuchiya, Hideo Kunimoto, Shizuka Kuno, Atsushi Fukunaga, Kaoru Yotsumoto, Takashi Tanaka, Kunitoshi Sakurai, Genryu Hirano, Keiji Yokoyama, Shinya Nishizawa, Makoto Yoshikane, Akira Anan, Yasuaki Takeyama, Yuji Kitamura, Kaoru Iwata, Makoto Irie, Satoshi Shakado, Tetsuro Sohda, Shotaro Sakisaka. Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate.
European journal of gastroenterology & hepatology.
2015 Jan; 27(1):55-64. doi:
10.1097/meg.0000000000000208. [PMID: 25370853] - Dorota Kozielewicz, Dorota Dybowska, Kornelia Karwowska, Magdalena Wietlicka-Piszcz. Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors.
Expert opinion on drug safety.
2015; 14(12):1815-25. doi:
10.1517/14740338.2015.1102882. [PMID: 26513231] - Véronique Loustaud-Ratti, Annick Rousseau, Paul Carrier, Chanlina Vong, Tristan Chambaraud, Jérémie Jacques, Marilyne Debette-Gratien, Denis Sautereau, Marie Essig. eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance?.
Liver international : official journal of the International Association for the Study of the Liver.
2015 Jan; 35(1):71-8. doi:
10.1111/liv.12631. [PMID: 25039814] - Laurent Cotte, Aurélie Barrail-Tran, Corine Vincent, Marc-Antoine Valantin, Isabelle Fournier, Karine Lacombe, Stéphane Chevaliez, Jean-Pierre Aboulker, Anne-Marie Taburet, Jean-Michel Molina. Telaprevir enhances ribavirin-induced anaemia through renal function impairment.
Antiviral therapy.
2015; 20(5):479-86. doi:
10.3851/imp2929. [PMID: 25560644] - David A Goodkin, Brian Bieber. Hemodialysis patients with hepatitis C infection are not receiving the new antiviral medications.
American journal of nephrology.
2015; 41(4-5):302. doi:
10.1159/000432408. [PMID: 26044708] - Harald Farnik, Nerea Ferreirós, Sandra Labocha, Gerd Geisslinger, Stefan Zeuzem, Christoph Sarrazin, Johannes Vermehren. Role of telaprevir plasma levels for predicting response to antiviral therapy in patients with hepatitis C virus genotype 1 infection.
Scandinavian journal of gastroenterology.
2014 Dec; 49(12):1473-9. doi:
10.3109/00365521.2014.978363. [PMID: 25384840] - Xinhui Chen, Lane R Bushman, Kevin J McAllister, Peter L Anderson, Jennifer J Kiser. Validation of a sensitive LC/MS/MS method for the determination of telaprevir and its R-isomer in human plasma.
Biomedical chromatography : BMC.
2014 Dec; 28(12):1714-21. doi:
10.1002/bmc.3211. [PMID: 24760592] - Andrew H Talal, Rositsa B Dimova, Eileen Z Zhang, Min Jiang, Marina S Penney, James C Sullivan, Martyn C Botfield, Ananthsrinivas Chakilam, Rishikesh Sawant, Christine M Cervini, Marija Zeremski, Ira M Jacobson, Ann D Kwong. Telaprevir-based treatment effects on hepatitis C virus in liver and blood.
Hepatology (Baltimore, Md.).
2014 Dec; 60(6):1826-37. doi:
10.1002/hep.27202. [PMID: 24811404] - Hamid Hasson, Emanuela Messina, Marco Merli, Liviana Della Torre, Giulia Morsica, Sabrina Bagaglio, Adriano Lazzarin, Caterina Uberti-Foppa. Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
2014 Dec; 29(?):100-2. doi:
10.1016/j.ijid.2014.08.011. [PMID: 25449243] - Toru Ikegami, Tomoharu Yoshizumi, Masaki Kato, Satomi Yamamoto, Takasuke Fukuhara, Yoshiharu Matsuura, Shota Nakamura, Shinji Itoh, Ken Shirabe, Yoshihiko Maehara. Reduced-dose telaprevir-based triple antiviral therapy for recurrent hepatitis C after living donor liver transplantation.
Transplantation.
2014 Nov; 98(9):994-9. doi:
10.1097/tp.0000000000000166. [PMID: 25099704] - Sarah Aherfi, Caroline Solas, Anne Motte, Jacques Moreau, Patrick Borentain, Saadia Mokhtari, Danielle Botta-Fridlund, Catherine Dhiver, Isabelle Portal, Jean-Marie Ruiz, Isabelle Ravaux, Sylvie Bregigeon, Isabelle Poizot-Martin, Andreas Stein, René Gérolami, Philippe Brouqui, Catherine Tamalet, Philippe Colson. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
Journal of medical virology.
2014 Nov; 86(11):1868-76. doi:
10.1002/jmv.24016. [PMID: 25052594] - Mark Johnson, Julie Borland, Shuguang Chen, Paul Savina, Brian Wynne, Stephen Piscitelli. Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir.
British journal of clinical pharmacology.
2014 Nov; 78(5):1043-9. doi:
10.1111/bcp.12428. [PMID: 24838177] - Mary Beth Wire, Lei Fang, Azra Hussaini, Joseph F Kleha, Dickens Theodore. Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.
Antimicrobial agents and chemotherapy.
2014 Nov; 58(11):6704-9. doi:
10.1128/aac.03091-14. [PMID: 25155600] - J Slim, N Scangarello, P Samaha, J Dazley. A case of sustained virologic response of HCV with telaprevir-based therapy in a patient with HIV and end stage kidney disease.
International journal of STD & AIDS.
2014 Oct; 25(11):830-2. doi:
10.1177/0956462414521164. [PMID: 24557545] - Amedeo De Nicolò, Lucio Boglione, Alessia Ciancio, Jessica Cusato, Silvia Strona, Chiara Simona Cardellino, Adnan Mohamed Abdi, Giuseppe Cariti, Giulia Troshina, Gian Paolo Caviglia, Antonina Smedile, Mario Rizzetto, Giovanni Di Perri, Antonio D'Avolio. Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner.
Antiviral research.
2014 Sep; 109(?):7-14. doi:
10.1016/j.antiviral.2014.06.005. [PMID: 24956496] - Min Jiang, Eileen Z Zhang, Andrzej Ardzinski, Ann Tigges, Andrew Davis, James C Sullivan, Michelle Nelson, Joan Spanks, Jennifer Dorrian, Olivier Nicolas, Doug J Bartels, B Govinda Rao, Rene Rijnbrand, Tara L Kieffer. Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor.
Antimicrobial agents and chemotherapy.
2014 Sep; 58(9):5456-65. doi:
10.1128/aac.03052-14. [PMID: 24982088] - P Carrier, T Chambaraud, C Vong, A Guillaudeau, M Debette-Gratien, J Jacques, R Legros, D Sautereau, M Essig, V Loustaud-Ratti. Severe renal impairment during triple therapy with telaprevir.
Clinics and research in hepatology and gastroenterology.
2014 Sep; 38(4):e69-71. doi:
10.1016/j.clinre.2013.12.005. [PMID: 24461554] - Lionel Rostaing, Laurent Alric, Jacques Izopet, Nassim Kamar. What are the management issues for hepatitis C in dialysis patients?: hepatitis C virus infection and its treatment in patients with end-stage renal disease.
Seminars in dialysis.
2014 Sep; 27(5):451-5. doi:
10.1111/sdi.12290. [PMID: 25204878] - Masanori Atsukawa, Akihito Tsubota, Noritomo Shimada, Hiroshi Abe, Chisa Kondo, Norio Itokawa, Ai Nakagawa, Katsuhiko Iwakiri, Chiaki Kawamoto, Yoshio Aizawa, Choitsu Sakamoto. Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
2014 Aug; 46(8):738-43. doi:
10.1016/j.dld.2014.05.004. [PMID: 24880716] - Clara T M M de Kanter, Jan G den Hollander, Corrien P W G M Verweij-van Wissen, David M Burger. Telaprevir pharmacokinetics in a hepatitis C virus infected patient on haemodialysis.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
2014 Aug; 60(4):431-2. doi:
10.1016/j.jcv.2014.05.008. [PMID: 24929751] - Clara T M M de Kanter, Matthijs van Luin, Caroline Solas, David M Burger, Jan Maarten Vrolijk. Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.
Annals of hepatology.
2014 Jul; 13(4):452-5. doi:
10.1016/s1665-2681(19)30853-1. [PMID: 24927617] - Christophe Hézode, Helene Fontaine, Celine Dorival, Fabien Zoulim, Dominique Larrey, Valerie Canva, Victor De Ledinghen, Thierry Poynard, Didier Samuel, Marc Bourliere, Laurent Alric, Jean-Jacques Raabe, Jean-Pierre Zarski, Patrick Marcellin, Ghassan Riachi, Pierre-Henri Bernard, Veronique Loustaud-Ratti, Olivier Chazouilleres, Armand Abergel, Dominique Guyader, Sophie Metivier, Albert Tran, Vincent Di Martino, Xavier Causse, Thong Dao, Damien Lucidarme, Isabelle Portal, Patrice Cacoub, Jerome Gournay, Veronique Grando-Lemaire, Patrick Hillon, Pierre Attali, Thierry Fontanges, Isabelle Rosa, Ventzislava Petrov-Sanchez, Yoann Barthe, Jean-Michel Pawlotsky, Stanislas Pol, Fabrice Carrat, Jean-Pierre Bronowicki. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Gastroenterology.
2014 Jul; 147(1):132-142.e4. doi:
10.1053/j.gastro.2014.03.051. [PMID: 24704719] - Alexandre Pariente, André-Jean Rémy, Bruno Lesgourgues, Hervé Hagège. Risk factors for severe anaemia during telaprevir-based triple therapy: is acquired renal dysfunction the missing link?.
Liver international : official journal of the International Association for the Study of the Liver.
2014 Jul; 34(6):e163-4. doi:
10.1111/liv.12510. [PMID: 24571470] - Eva Van den Eynde, Elena Ferrer, Daniel Podzamczer. Acute renal failure and liver toxicity in an HIV/hepatitis C coinfected patient receiving telaprevir and boosted atazanavir.
AIDS (London, England).
2014 Jun; 28(10):1538-9. doi:
10.1097/qad.0000000000000265. [PMID: 24896804] - Adrian Curran, Josep Maria Guiu, Esteban Ribera, Manuel Crespo. Darunavir and telaprevir drug interaction: total and unbound plasma concentrations in HIV/HCV-coinfected patients with cirrhosis.
The Journal of antimicrobial chemotherapy.
2014 May; 69(5):1434-6. doi:
10.1093/jac/dkt509. [PMID: 24363317] - Thomas N Kakuda, Lorant Leopold, Steven Nijs, Ann Vandevoorde, Herta M Crauwels, Kirk M Bertelsen, Marita Stevens, James Witek, Yvon van Delft, Frank Tomaka, Richard M W Hoetelmans. Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.
Journal of clinical pharmacology.
2014 May; 54(5):563-73. doi:
10.1002/jcph.245. [PMID: 25975423] - T Karino, I Ozeki, S Hige, M Kimura, T Arakawa, T Nakajima, Y Kuwata, T Sato, T Ohmura, J Toyota. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C.
Journal of viral hepatitis.
2014 May; 21(5):341-7. doi:
10.1111/jvh.12162. [PMID: 24001168] - Manoli Vourvahis, Anna Plotka, Constantino Kantaridis, Annie Fang, Jayvant Heera. The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers.
Journal of acquired immune deficiency syndromes (1999).
2014 Apr; 65(5):564-70. doi:
10.1097/qai.0000000000000090. [PMID: 24346637] - L Boglione, A De Nicolò, J Cusato, G Cariti, G Di Perri, A D'Avolio. Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir.
Journal of viral hepatitis.
2014 Apr; 21(4):260-3. doi:
10.1111/jvh.12170. [PMID: 24597694] - Satheesh Nair, Bradford Waters. Telaprevir in treatment of recurrent hepatitis C infection in liver transplant recipients.
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.
2014 Apr; 12(2):117-22. doi:
NULL. [PMID: 24702143] - Norihiro Furusyo, Eiichi Ogawa, Masayuki Murata, Kazuhiro Toyoda, Hachiro Ohnishi, Kunimitsu Eiraku, Motohiro Shimizu, Yuji Harada, Fujiko Mitsumoto, Koji Takayama, Mosaburo Kainuma, Kyoko Okada, Jun Hayashi. Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response.
The Journal of antimicrobial chemotherapy.
2014 Feb; 69(2):483-90. doi:
10.1093/jac/dkt371. [PMID: 24092661] - Hidezumi Kikuchi, Hiroshi Numao. Telaprevir-induced acute kidney injury during treatment of chronic hepatitis C.
European journal of gastroenterology & hepatology.
2014 Feb; 26(2):244-5. doi:
10.1097/meg.0000000000000005. [PMID: 24366454] - Cristina Gervasoni, Laura Milazzo, Diletta Pezzani, Serena Fucile, Dario Cattaneo. Telaprevir therapy, renal impairment, and their effects on the pharmacokinetics of tenofovir in HIV/hepatitis C virus coinfected patients.
AIDS (London, England).
2014 Jan; 28(2):285-7. doi:
10.1097/qad.0000000000000088. [PMID: 24413314] - Alicia Gutierrez-Valencia, Rosa Ruiz-Valderas, Almudena Torres-Cornejo, Pompeyo Viciana, Nuria Espinosa, Juan R Castillo-Ferrando, Luis F Lopez-Cortes. Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2014 Jan; 58(2):268-73. doi:
10.1093/cid/cit693. [PMID: 24145880] - Yoshiiku Kawakami, Fumitaka Suzuki, Yoshiyasu Karino, Joji Toyota, Hiromitsu Kumada, Kazuaki Chayama. Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-α2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.
Antiviral therapy.
2014; 19(3):277-85. doi:
10.3851/imp2706. [PMID: 24192751] - Huiling Yang, Margaret Robinson, Amoreena C Corsa, Betty Peng, Guofeng Cheng, Yang Tian, Yujin Wang, Rowchanak Pakdaman, Marian Shen, Xiaoping Qi, Hongmei Mo, Chin Tay, Steve Krawczyk, X Christopher Sheng, Choung U Kim, Chris Yang, William E Delaney. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.
Antimicrobial agents and chemotherapy.
2014; 58(2):647-53. doi:
10.1128/aac.00487-13. [PMID: 23939899] - Tomohisa Nakada, Tomoko Kito, Katsuhisa Inoue, Satohiro Masuda, Ken-ichi Inui, Kazuo Matsubara, Yoshinori Moriyama, Noriko Hisanaga, Yasuhisa Adachi, Masayuki Suzuki, Ichimaro Yamada, Hiroyuki Kusuhara. Evaluation of the potency of telaprevir and its metabolites as inhibitors of renal organic cation transporters, a potential mechanism for the elevation of serum creatinine.
Drug metabolism and pharmacokinetics.
2014; 29(3):266-71. doi:
10.2133/dmpk.dmpk-13-rg-118. [PMID: 24390473]